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ABSTRACT

Backman, Patrick N. M.S., Purdue University, May 2016. Alternative Regulation of
MYC in Lung Cancer. Major Professor: Andrea Kasinski.

Lung cancer is the leading cause of cancer deaths in the United States, accounting
for 27% of all cancer induced deaths1. In an attempt to create a effective targeted therapy
for the treatment of lung cancer, a strategy used to treat an activated KrasG12D/+;p53R172H/+
transgenic lung cancer mouse model was to deliver a known tumor suppressive
microRNA (miRNA) to stop tumor growth. The tumor suppressive miRNA let-7 was
lentivirally delivered in the form of its primary transcript, pri-let-7a-1, and resulted in
increased lung size and inflammation compared to lungs exposed to a control lentivirus.
It was identified that LIN28B transcripts were elevated in this transgenic model2 and a
truncated MYC protein product, separate from canonical MYC, was overexpressed with
activation of the transgenic lung cancer mouse model. LIN28B is a pluripotent factor and
post-transcriptional inhibitor of let-7 biogenesis3–5. Therefore, it was hypothesized that
the LIN28B mediated accumulation of pri-let-7a-1 transcripts promoted expression of the
truncated MYC protein product, termed T-MYC. Through this work, it was determined
that T-MYC expression is not dependent on the LIN28B mediated accumulation of prilet-7a-1 transcripts and that T-MYC is likely not a variant of canonical MYC.
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CHAPTER 1: INTRODUCTION

Lung cancer is the largest contributor to the total number of cancer deaths
worldwide with an estimated 158,040 deaths in the United States in 2015; 26.8% of all
cancer associated deaths.

Additionally, the number of new lung cancer diagnoses

increases every year with an estimated 221,200 new cases in 2015 alone1. Despite efforts
to create effective therapies for the treatment of lung cancer, the five-year survival rate
for patients with this cancer type remains at a dismal 17%1. This poses a great challenge
to both the medical and scientific communities to elucidate the underlying causes of lung
cancer.
Patients who are diagnosed with lung cancer are typically recommended to
undergo initial treatments that are more general in nature. This often includes measures
such as the surgical removal of tumor tissue from the lungs in early stages of disease
progression and chemotherapy or radiation therapy6. A major limitation in utilizing these
techniques as a means of treating the disease is that lung cancer is typically not detected
until later stages of progression, a point in time when metastatic disease is much more
likely. This creates a situation in which traditional treatment measures, i.e. surgery,
chemotherapy, and radiation therapy, are much less effective in halting lung cancer
growth and progression7. In an effort to combat this problem, a great deal of research
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effort has been expended on developing therapies that are specific and more effective in
treating late-stage lung cancer, a more aggressive disease state.
Lung cancer, when diagnosed, is categorized into one of several subtypes
depending on its clinical presentation. Non-small cell8, small cell9, and lung carcinoid
tumors10 are the subgroups that are used clinically to classify lung cancers. Non-small
cell lung cancer (NSCLC) is the most prevalent type, comprising approximately 80% of
diagnosed lung cancers. This lung cancer subtype encompasses several types of cancers,
including squamous cell carcinoma, large cell carcinoma, and adenocarcinoma11.
It is well known that the molecular landscape within a cancer cell is dysregulated
when compared to its normal, healthy counterpart; that is, many normal cellular processes
and molecular mechanisms are altered in cancer and much of this alteration has been
established as being crucial for the development, maintenance, and growth of cancer. In
cancer, this often results in the up- or down-regulation of factors that are important for
development as well as maintaining a differentiated cellular state. Factors that are down
regulated in cancer and are important for limiting cellular growth and promoting
processes that result in cellular death are called tumor suppressors.

Vice-versa,

oncogenic factors are up regulated in cancer and allow cells to overcome processes that
are important in controlling how cells grow and eventually die12. Efforts to create a
targeted therapy for cancer are often focused on either the reintroduction of tumorsuppressive factors in a background where they are lost or blocking the action of
oncogenic factors that are up regulated in a cancer type.
The major drugs currently on the market for the targeted treatment of late stage
non-small cell lung cancer focus on blocking the action of such oncogenic factors.
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Gefitinib and erlotinib are small molecule inhibitors that specifically target and block the
action of the epidermal growth factor receptor, EGFR13. EGFR is a gene that has been
found to be mutated and upregulated in approximately 43-89% of NSCLC tumors14 and
is responsible for activating signaling that promotes cell growth14. While it has been
demonstrated that these drugs are effective in inhibiting the action of EGFR, their
effectiveness is limited to lung cancers with EGFR upregulation. There are additional
targeted therapies for the treatment of lung cancer, but they also rely on the upregulation
of specific oncogenic factors that have implications in promoting lung cancer
progression15,16. Inhibitors that block the anaplastic lymphoma kinase, ALK, are also
used for the targeted treatment of lung cancer but are more limited as ALK
rearrangements implicated in cancer formation are seen in approximately 2-7% of
NSCLC tumors15,17,18. This poses a significant challenge to researchers to elucidate
additional mechanisms that are widely activated in lung cancer that could serve as a basis
of therapeutic intervention.
MYC is a family of proto-oncogenic transcription factors that have been
established to be important in development and are also implicated in promoting
cancer19–21. The increased expression of MYC, through varying mechanisms, is observed
in approximately 30% of all cancers, signifying its importance and broad impact as an
oncogene22,23.

When expressed, MYC forms a dimer with a protein, MAX, that

positively regulates the effects of MYC, binds to E-box sequences contained within the
promoters of genes, and mediates transcriptional changes to its target genes24,25. Studies
focused on understanding exactly what genes MYC regulates have revealed its ability to
influence the expression of a large number of genes, especially ones that are already
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being actively transcribed within a cell26,27. The response of cells to increased expression
of MYC include, but are not limited to, changes in processes that promote cancer such as
inducing cell cycle progression, influencing apoptosis, decreasing genomic stability, and
enhancing cell growth28. The broad reaching effects of MYC on cells make it not only an
important oncogene but therapeutically intervening on its action could prove to be an
invaluable asset in the treatment of many different cancer types, including lung cancer.
Interestingly, there are several family members of MYC that have varying
abilities of producing the pro-tumorigenic phenotype associated with MYC’s oncogenic
function.

Of the family members, only N-MYC, c-MYC, and L-MYC have been

demonstrated to have the potential to lead to neoplastic growth when expressed in
cancer29. c-MYC is expressed in many different cancer types, L-MYC is expressed in
small cell lung cancer30, and N-MYC expression is seen in neuroblastoma31.
Additionally, there are protein products that arise from alternative translation of MYC
mRNA. These products are collectively called MYC-S and are truncated versions of cMYC, lacking the N terminus of the canonical protein product. It has been demonstrated
that these products have the ability to form a dimer with Max, the positive regulator of
MYC, and inhibit transactivation of transcription of canonical MYC targets32,33.
Together, this demonstrates one facet of the complexity surrounding the biology of MYC
and its family members within the context of cancer.
In an effort to understand the regulatory mechanisms MYC’s expression
influences, it was identified that one subset of transcripts that MYC regulates is that of
microRNAs (miRNAs)34. miRNAs are small, 18-24 nucleotide, non-coding RNAs that
are transcribed in the nucleus as a longer primary miRNA transcript (pri-miRNA) and
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Figure 1: Canonical microRNA biogenesis pathway. The primary miRNA is
transcribed by RNA Polymerase II and forms the characteristic hairpin-loop structure.
The flanking regions of the transcript are cleaved by DROSHA and DGCR8 to form the
precursor miRNA. The precursor miRNA is then exported into the cytoplasm where it is
further cleaved by DICER. The guide strand is then loaded into Argonaute and further
associates with the RNA Induced Silencing Complex to mediate mRNA degradation or
inhibition of translation of mRNA targets.
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form a hairpin loop structure, as seen in Figure 135. The pri-miRNA is then processed
into a shorter transcript, termed the precursor miRNA (pre-miRNA), by the RNAse
processing enzyme DROSHA. The pre-miRNA is exported into the cytoplasm where it
undergoes further cleavage into a double stranded RNA molecule by another RNase
enzyme, DICER36. The guide strand of the miRNA duplex is then loaded into Argonaute,
a component of the RNA Induced Silencing Complex (RISC). RISC is then poised for
the post-transcriptional down-regulation of gene expression, and ultimately protein
expression, through base complementarity of the mat-miRNA with its target messenger
RNAs (mRNAs)36,37.

miRNA mediated regulation of genes signifies an important

regulatory mechanism that contributes to maintaining cellular states in development and
differentiation and is a mechanism that is highly dysregulated in cancer.
Accordingly, MYC can both up- and down-regulate the expression of both tumor
suppressive and oncogenic miRNAs, which can influence the fate of cells. For example,
MYC has been shown to directly cause the expression of miR-17-92, an oncogenic
miRNA cluster, which contributes to the tumorigenic phenotype associated with MYC by
regulating genes that control chromatin modifications38. Alternatively, MYC also causes
down-regulation of miRNAs important in controlling a proliferative phenotype, such as
the tumor suppressive miRNA let-7. let-7 was originally identified in Caenorhabditis
elegans as an important developmental regulator and was later found to be conserved in
humans. let-7 expression is commonly down-regulated or lost in cancer, allowing for the
uncontrolled expression of its target proto-oncogenes such as KRAS, MYC, and
LIN28B39–42. As seen in Figure 2, MYC directly causes the expression of LIN28B, which
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Figure 2: Negative feedback regulation of MYC, LIN28B, and let-7. In a
differentiated cell, canonical let-7 processing occurs allowing the negative regulation of
MYC and LIN28B. In cancer, the expression of MYC promotes LIN28B expression,
blocking the biogenesis of mat-let-7a, therefore losing the negative regulation of MYC
and LIN28B.
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in turn blocks the processing of let-7 due to LIN28B being a post-transcriptional inhibitor
of let-7 biogenesis. This signifies an important negative feedback loop where in a
differentiated cell, let-7 targets and down-regulates both MYC and LIN28B but in a
neoplastic state, such as cancer, the expression of these oncogenes is uncontrolled3,39.
The overexpression of MYC and subsequently LIN28B then causes the decreased
maturation of let-73. MYC expression causes large changes in regulatory mechanisms
that contribute to the tumorigenic state often associated with expression of this oncogene
in cancers. Restoring regulatory mechanisms that are dysregulated by MYC not only
contributes to understanding the role of MYC in cancer, but could also reveal potential
therapeutic targets for the treatment of cancer.
Therapies have been developed to directly block the action of MYC within cancer
which includes strategies to create small molecule inhibitors of MYC-Max dimerization43
as well as targeting upstream mechanisms that influence MYC’s expression and activity44.
Creating effective targeted therapies against transcription factors has proven to be
difficult due to the fact that they lack enzymatic activity, thus having less specific drug
targets within their protein structure45. In the past few years, however, the therapeutic
potential of using miRNAs as an intervention has shown promising results46–48. miRNAs
as a whole can be classified as either being tumor suppressive or oncogenic. Tumor
suppressive miRNAs usually down regulate processes that contribute to cancer and their
expression is decreased or nonexistent in cancer. Oncogenic miRNAs are overexpressed
in cancer and their expression results in a pro-tumorigenic phenotype46,48. Due to the fact
that a single miRNA has many mRNA targets37, the reintroduction of a single tumor
suppressive miRNA or blocking the action of an oncogenic miRNA could mimic a drug

9
cocktail through reestablishing the canonical regulation of many genes at once. This has
been demonstrated with the miRNA, miR-34, a tumor suppressive miRNA commonly
down regulated in cancer49.

A miR-34 mimic is currently in clinical trials for the

treatment of cancer due to its demonstrated ability to inhibit cellular processes that
contribute to tumor formation and growth50,51. There is great potential in exploiting the
use of miRNAs as a cancer therapy not only to reestablish tumor suppressive mechanisms
but to also block oncogenic processes occurring within cancer. miRNA therapies could
greatly contribute to the treatment of lung cancer, an aggressive cancer type with few
effective therapeutic options.
To test the effectiveness in using microRNAs (miRNAs) as a therapeutic
intervention, it was hypothesized that a tumor suppressive miRNA could be exogenously
delivered and halt tumor progression. The lung cancer model being studied was a
KrasG12D/+;p53R172H/+ transgenic mouse model.

The transgenes in this model are

activated through genomic recombination of loxP sites with Cre Recombinase and results
in production of mutant Kras and p53. KRAS mutation, and subsequent overexpression,
has direct implications in lung cancer and is found in approximately 30% of lung
adenocarcinomas52. TP53 encodes the tumor suppressive protein p53 that is the most
commonly perturbed gene in cancer, mutated in approximately 40% of all lung cancers 53.
To test the hypothesis that a tumor suppressive miRNA could halt tumor growth in this
model,

unprocessed,

pri-let-7a-1

was

lentivirally delivered

to

the

activated

KrasG12D/+;p53R172H/+ transgenic mouse model. Primary-let-7a-1 (pri-let-7a-1) is the full
length transcript of let-7a that requires processing through the canonical miRNA
biogenesis pathway, Figure 1, to mediate the tumor suppressive function of let-7 through
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its mature transcript, mat-let-7a. The response seen with the lentiviral delivery of pri-let7a-1 was increased lung size and inflammation compared to lungs exposed to a lentiviral
control, as seen in Figure 3. This result was in strict contrast to the hypothesis that prilet-7a-1 would be processed through the canonical miRNA biogenesis pathway, seen in
Figure 2, and mat-let-7a and would subsequently downregulate its target oncogenes and
ultimately halt tumor progression.
It was later determined in the KrasG12D/+;p53R172H/+ transgenic model that LIN28B
transcripts were overexpressed2. LIN28B is a post-transcriptional regulator of let-7 that
blocks maturation of let-7 sequences, negating the tumor suppressive capabilities of let74,5,54,55. It was hypothesized that let-7 targets would be dysregulated in this model due to
the LIN28 mediated inhibition of let-7 biogenesis. To determine if let-7a targets were
dysregulated in the KrasG12D/+;p53R172H/+ activated transgenic mouse model, lung tissue
was assessed for the presence of MYC, a known oncogene that is targeted and downregulated by mat-let-7a39,56. In tissues of a non-activated (normal) lung compared to
lungs harvested from the KrasG12D/+;p53R172H/+ activated model of lung tumor formation,
the expression of canonical MYC was not affected. Interestingly, however, a truncated
form of MYC was detected as being overexpressed in the activated tumor model
compared to the normal lung tissue, seen in Figure 4. This led to the overall hypothesis of
this work that the LIN28B mediated accumulation of pri-let-7a-1 promoted the
expression of a truncated form of MYC. To test this hypothesis, this work is divided into
two main areas. First, since it was hypothesized that the truncated MYC protein product
was indeed a variant of MYC, this protein was characterized. Secondly, the ability of prilet-7a-1 to induce the expression of this truncated MYC protein was evaluated.
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Figure 3: Lentivirally delivered pri-let-7a-1 increases lung size. Pri-let-7a-1 was
lentivirally delivered to a KrasG12D/+;p53R172/+ lung cancer mouse model, lungs were
weighed and normalized to the total weight of the animal compared to lungs exposed to a
control lentivirus.

12

Figure 4: A truncated MYC protein product is induced in the KrasG12D/+;p53R172/+
lung cancer mouse model. Transgenic mice were administered adenovirus-cre and
tumor formation progressed for 19 weeks. Protein was extracted and assessed for the
expression of MYC compared to non-tumorigenic lungs by SDS-PAGE and
immunoblotting.
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CHAPTER 2: CHARACTERIZATION OF THE TRUNCATED MYC PROTEIN
PRODUCT, T-MYC

Activation of the KrasG12D/+;p53R172H/+ transgenic mouse model causes expression
of mutated Kras and p53 which leads to tumor formation2. Molecularly, it was identified
that a truncated variant of canonical MYC, termed T-MYC, was also overexpressed upon
activation of this lung cancer model. As a means of determining if T-MYC was indeed a
truncated variant of canonical MYC, several strategies were implemented to characterize
this novel protein product.
The expression of T-MYC was first identified in vivo and was hypothesized to be
induced by the accumulation of pri-let-7a-1 through LIN28B. To test that the expression
of the truncated form of MYC, termed T-MYC, could be replicated in vitro, the lentiviral
plasmid that expresses the pri-let-7a-1 sequence was transfected into A549 and Calu6
lung adenocarcinoma cell lines, both which have detectable levels of LIN28B expression.
After transfection of lenti-pri-let-7a-1 as well as a control lentiviral plasmid, cell lysates
were assessed for the presence of T-MYC through SDS-PAGE and immunoblotting. As
seen in Figure 5, T-MYC expression was induced in both A549 and Calu6 cell lines when
the lenti-pri-let-7a-1 plasmid was transfected compared to lysates obtained from cells
transfected with the control lentiviral plasmid. This finding confirmed that T-MYC
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Figure 5: T-MYC expression is induced in cell culture. A control lentiviral plasmid or
lenti-pri-let-7a-1 was transfected in A549, A., and Calu6, B., lung adenocarcinoma cells.
48hrs post-transfection cells were lysed and protein was analyzed for the expression of TMYC through SDS-PAGE and immunoblotting.
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expression could be duplicated in vitro and signified its potential as a contributor to the
pro-tumorigenic phenotype seen when lenti-pri-let-7a-1 was transduced in vivo.
In an effort to further validate T-MYC as an alternate form of canonical MYC,
several strategies were utilized. The first strategy was to simply determine if T-MYC
could be detected through immunoblotting with several different primary antibodies
generated to bind MYC. To do so, T-MYC expression was induced by transfection of the
lenti-pri-let-7a-1 plasmid in A549 cells and compared to cells transfected with a control
lentiviral plasmid. Cellular lysates obtained post-transfection were assessed through
SDS-PAGE and immunoblotting for the presence of T-MYC expression using several
different primary antibodies that detect human MYC. Three antibodies were used to
detect MYC, one that was generated to bind an epitope closer to the N-terminus of MYC
made by Cell Signaling and two that were generated to recognize and bind closer to the
C-terminus of MYC made by Sigma Aldrich and Abcam. Interestingly, T-MYC was
detected only using antibodies generated to bind epitopes on the C-terminus of MYC, as
seen in Figure 6. This finding suggested that T-MYC was a protein variant of canonical
MYC and that it was lacking most of the N-terminus but retained the C-terminus of
canonical MYC within its protein structure.
Small-interfering RNA (siRNA) mediated knock-down of T-MYC was a final
strategy employed to understand if T-MYC was in fact a protein variant of MYC. It was
hypothesized that if T-MYC is a truncated form of canonical MYC, then it would be
knocked down with an siRNA that also knocks down canonical, full-length MYC. To
test this hypothesis, A549 cells were co-transfected with either a control or lentiviral-pri-
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Figure 6: T-MYC is detected with two antibodies generated to detect the C-terminus
of MYC. A549 lung adenocarcinoma cells were transfected with a control lentiviral
plasmid or lenti-pri-let-7a-1. 48hrs post transfection, cells were lysed and protein
extracted was assessed for the presence of T-MYC through SDS-PAGE and
immunoblotting. Antibody 1 (Ab1) was produced by Cell Signaling, Antibody 2 (Ab2)
by Sigma Aldrich and Antibody 3 (Ab3) by Abcam.
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let-7a-1 plasmid along with a control, scrambled, siRNA or one of two siRNAs designed
to target and downregulate MYC. After transfection, cell lysates were obtained and
assessed for both canonical MYC and T-MYC expression through SDS-PAGE and
immunoblotting.

As seen in Figure 7, canonical MYC expression was only

downregulated when the siRNAs targeting c-MYC was co-transfected, as expected. On
the other hand, T-MYC was induced when the lenti-pri-let-7a-1 plasmid was transfected
into the cells, but its expression was not affected by co-transfection of the siRNA
targeting the

end of the MYC transcript. However, T-MYC was knocked down with co-

transfection of the siRNA targeting the

end of the MYC transcript. This finding

indicated that a transcript variant of MYC induced by pri-let-7a-1 expression was possibly
responsible for the expression of T-MYC.
To further investigate the possibility that a MYC transcript variant was responsible
for the induction of T-MYC, it was hypothesized that the expression of total MYC
transcripts would increase with the transfection of lenti-pri-let-7a-1.

To test this

hypothesis, protein and RNA were extracted after co-transfection of lenti-pri-let-7a-1
with a scrambled, control siRNA or a siRNA targeting the

end of MYC transcripts and

compared to transfection with a control lentiviral plasmid in A549 lung adenocarcinoma
cells. Protein was extracted from cell lysates and assessed for the expression of canonical
MYC and T-MYC through SDS-PAGE and immunoblotting. As seen in Figure 8A, the
expression of canonical MYC was decreased with co-transfection of the siRNA targeting
MYC, as expected. The expression of T-MYC was induced by transfection of lenti-prilet-7a-1 and was unchanged by co-transfection of the siRNA targeting the

end of MYC,

as seen previously. Once it was confirmed that the expression of T-MYC was seen with

18

Figure 7: T-MYC is possibly expressed from a transcript variant of the canonical
MYC transcript. A549 lung adenocarcinoma cells were cotrasfected with lenti-pri-let7a-1 and either a control, scrambled siRNA or a siRNA targeting MYC. Lysates were
assessed for the expression of canonical MYC and T-MYC through SDS-PAGE and
immunoblotting.
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Figure 8: T-MYC is not a transcript or protein variant of canonical MYC. A549
lung adenocarcinoma cells were co-transfected with a control lentiviral plasmid or lentipri-let-7a-1 and a control siRNA or a siRNA targeting Myc. 48hrs post-transfection
protein and RNA were extracted. A. Protein was assessed for the expression of T-Myc
through SDS-PAGE and immunoblotting. B. RNA was reverse transcribed and used in
qPCR with primers spanning the two exon junctions in MYC, MYC Exon 1/2 and MYC
Exon 2/3. Β-Actin was used as the normalizer for gene expression and the control
plasmid/control siRNA transfection served as the internal control. Error bars were
generated by calculating the standard deviation of expression values obtained by utilizing
the comparative Ct method with the control plasmid, control siRNA transfection serving
as the internal control. Significance was determined through subjecting expression values
to one-way ANOVA in GraphPad Prism. ** p < .01.
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the transfection of lenti-pri-let-7a-1, the RNA also extracted from the cells after
transfection underwent reverse transcription and was utilized in qPCR to further
understand if a MYC transcript variant was induced by lenti-pri-let-7a-1. Two primer sets
were used in qPCR, one that spanned the junction between exons 1 and 2 in MYC, MYC
Exon1/2, and one primer pair that spanned the junction between exons 2 and 3 in MYC,
MYC Exon2/3. As seen in Figure 8B, the expression of MYC was unchanged when lentipri-let-7a-1 was transfected compared to the lentiviral control transfection. When lentipri-let-7a-1 was co-transfected with the siRNA targeting MYC, however, the expression
of MYC decreased. Since T-MYC expression was observed with transfection of lenti-prilet-7a-1 but there was no change in the expression of MYC, the hypothesis that a
transcript variant was being expressed was false. Additionally, the co-transfection of
lenti-pri-let-7a-1 with the siRNA targeting MYC resulted in the decreased expression of
the MYC protein product as well as MYC transcripts but the expression of T-MYC was
unchanged. This indicated that T-MYC is likely not a protein or transcript variant of
canonical MYC.
Although the expression of T-MYC was clearly induced by the transfection of
lenti-pri-let-7a-1 and detected with multiple antibodies that bind MYC, it was determined
that T-MYC was not a protein or transcript variant of canonical MYC. The detection of
T-MYC may be explained simply by conservation of the region that both the antibodies
recognized. The c-terminus of MYC contains a basic helix-loop-helix (bHLH) domain,
which is part of diverse family of transcription factors that also contain this domain57–59.
It is possible that the transfection of lenti-pri-let-7a-1 causes the induction of another
bHLH containing protein that is detected by MYC antibodies that bind this domain.
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Regardless, while T-MYC is likely not a variant of canonical MYC the implications of its
expression in lung cancer has yet to be elucidated in regards to its expression seen in vivo.

22

CHAPTER 3: EVALUATING THE ABILITY OF PRI-LET-7A-1 TO INDUCE
EXPRESSION OF T-MYC

The expression of T-MYC was first seen in vivo upon activation of a
KrasG12D/+;p53R172H/+ mouse model and later when a lentiviral plasmid expressing
primary-let-7a-1 (pri-let-7a-1) was transfected in cell culture. The induction of T-MYC
expression was consistently seen in backgrounds where LIN28B was also expressed
which led to the hypothesis that the accumulation of pri-let-7a-1 through LIN28B
promoted the expression of T-MYC. Several strategies were used to understand if TMYC expression was dependent upon pri-let-7a-1 and LIN28B.
Since T-MYC expression was induced with the transfection of the lentiviral
plasmid that expresses pri-let-7a-1, it was initially hypothesized that pri-let-7a-1 induced
expression of T-MYC. Several plasmids were created based on the lenti-pri-let-7a-1
plasmid to test if T-MYC expression was dependent on pri-let-7a-1. First, pri-let-7a-1
was excised from the lentiviral plasmid, lenti-pri-let-7a-1, and named lenti-Δpri-let-7a-1.
An additional plasmid was created in which pri-let-7a-1 was cloned from lenti-pri-let-7a1 into a non-lentiviral expression backbone and named pPNB-1. These constructs, along
with a lentiviral plasmid that expresses pri-let-7b, were transfected into H441 and A549
lung adenocarcinoma cells. It was hypothesized that only the plasmids that expressed
pri-let-7a-1 would induce the expression of T-MYC in A549 cells and not H441 since
A549 cells have detectable levels of LIN28B expression while H441 cells do not. As
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seen in Figure 9, T-MYC expression was induced only by the lenti-pri-let-7a-1 and lentiΔpri-let-7a-1 in both A549 and H441 lung adenocarcinoma cells. This result indicated
that T-MYC expression is not dependent upon pri-let-7a-1 expression or to other let-7
family members, but is inherent to the lentiviral backbone. Additionally, since T-MYC
expression was seen in both A549 and H441 cells, its expression is therefore not
dependent upon pri-let-7a-1 or LIN28B expression.
The preliminary data generated in vivo shows that T-MYC expression was
induced when the KrasG12D/+;p53R172/+ model was activated through transduction with
adenovirus Cre Recombinase, as seen in Figure 2. This in combination with the finding
that the lentiviral backbone was responsible for inducing expression of T-MYC, Figure 6,
led to the hypothesis that T-MYC expression may be conserved and inherent to
transduction with viral particles. To test this, A549 cells were transduced with lentivirus
and adenovirus and their cell lysates were probed for T-MYC through SDS-PAGE and
immunoblotting. As seen in Figure 10, T-MYC was induced with transfection of the
positive control, lenti-pri-let-7a-1, but not when transduced with lentivirus or adenovirus.
These findings indicate that T-MYC expression is not induced by transduction of cells
with lentivirus and adenovirus. The induced expression of T-MYC is inherent to the
original lentiviral backbone that was used to overexpress genes of interest.
One caveat of this study that was identified was the fact that T-MYC expression is
only induced in cell culture by transfection of lenti-pri-let-7a-1 and that transfection of
the lentiviral control plasmid did not promote expression of T-MYC. In the original
study determining the effectiveness of the lentiviral delivery of pri-let-7a-1, the original
lentiviral plasmids used for studying this effect were an older system created by System
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Figure 9: T-MYC expression is independent of pri-let-7a-1. H441, A., and A549, B.,
lung adenocarcinoma cells were transfected with plasmids that expressed (lenti-pri-let7a-1, pPNB-1) and did not express pri-let-7a-1 (Lenti-control, lenti-Δpri-let-7a-1 and
lenti-let-7b). 48hrs post transfection, cells were lysed and protein was assessed for the
expression of T-MYC through SDS-PAGE and immunoblotting.
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Figure 10: T-MYC expression is not induced by viral transduction in cell culture.
H441 lung adenocarcinoma cells were transfected with a control lentiviral plasmid or
lenti-pri-let-7a-1, or were transduced with lentivirus or adenovirus. 48hrs post
transfection cells were lysed and protein was extracted and assessed for T-MYC and βActin expression through SDS-PAGE and immunoblotting.
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Biosciences. When trying to propagate and transfect the lentiviral control, the plasmid
was difficult to prepare at working concentrations and failed when used to try to create
lentivirus for transduction in vivo. Thus, an updated lentiviral control was obtained from
System Biosciences while pri-let-7a-1 was still used in the older plasmid system. This
indicates that T-MYC expression is somehow only inherent to the older lentiviral plasmid
system by System Biosciences and T-MYC expression is not induced by the updated
lentiviral system.
It was hypothesized that the accumulation of pri-let-7a-1 through LIN28B
expression induced the expression of T-MYC. However, it was determined that T-MYC
expression is not dependent upon the expression pri-let-7a-1 or LIN28B. The expression
of T-MYC is promoted simply by the transfection of the lentiviral plasmid void of pri-let7a-1, indicating that T-MYC expression inherent to a component of the older lentiviral
backbone created by System Biosciences.
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CHAPTER 4: CONCLUSION

The treatment of lung cancer is currently an area that represents a great deal of
research effort both in academia and industry due to the fact that lung cancer is currently
responsible for more cancer deaths per year than any other cancer type. In the United
States in 2015, it was estimated that there would be 158,040 lung cancer deaths with an
additional 221,200 new diagnoses1. Those who are diagnosed with lung cancer are faced
with a 17% 5-year survival rate mainly due to most lung cancer cases not being detected
until later stages of cancer progression1. A later diagnosis indicates a point in time when
metastasis is much more likely, meaning a less treatable and much more aggressive time
in disease progression. Creating effective targeted therapies for the treatment of lung
could greatly increase the 5-year survival rate of lung cancer patients and decrease the
number of lung cancer associated deaths in the United States and globally.
One strategy for the targeted treatment of lung cancer that has shown promising
results is the use of microRNAs (miRNAs) as a therapeutic intervention. miRNAs are
transcribed from the genome into a long, primary microRNA (pri-miRNA) and undergo
further processing in the nucleus and cytoplasm, respectively, to form a shorter 18-24
nucleotide mature microRNA (mat-miRNA) duplex. The guide strand of the duplex then
associates with the RNA induced silencing complex (RISC) and through base
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complementarity with messenger RNAs (mRNAs), mediates the post transcriptional
down-regulation of protein expression through mRNA degradation or blocking
translation of mRNA targets37. Tumor suppressive miRNAs typically have decreased
expression in cancer compared to normal, healthy tissue and function by targeting and
regulating the expression of factors that promote tumorigenic processes. Oncogenic
miRNAs have increased expression in cancer compared to normal tissues and target
factors that are important in promoting anti-tumorigenic effects46,48.

Therefore, the

reintroduction of a tumor suppressive miRNA into a background where its expression is
lost or blocking the action of an oncogenic miRNA could restore the regulation of many
genes at one since one miRNA has many mRNA targets37.
let-7 is a tumor suppressive miRNA that has been observed to have decreased
expression in many cancer types60,61. The ability of a let-7 mimic to decrease the
tumorigenic phenotype seen in cancer has also been demonstrated in vivo61. These
findings led to the hypothesis that the exogenous delivery of let-7 would be advantageous
in treating an aggressive lung cancer mouse model. The model being studied was a
KrasG12D/+;p53R172H/+ transgenic mouse model that is activated by the recombination of
loxP sites with exposure to adenovirus-cre recombinase. Activation of this model results
in the constitutive expression of a mutated form of Kras, a known oncogene52,62, and
mutation of the tumor suppressive factor p5353. To test the hypothesis that let-7 could be
exogenously delivered to this model and stop tumor growth and progression, primary-let7a-1 (pri-let-7a-1) was lentivirally delivered to the activated KrasG12D/+;p53R172H/+
transgenic mouse model. Primary-let-7a-1 (pri-let-7a-1) is the unprocessed transcript of
let-7 that requires processing by cellular machinery to form its mature transcript, mat-let-
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7a, and mediate its proven tumor suppressive capabilities37. The effect seen with the
lentiviral transduction of pri-let-7a-1 was increased lung size and inflammation compared
to lungs exposed to a control lentivirus. This result went against the hypothesis that prilet-7a-1 would be processed into mat-let-7a, target oncogenes and mediate a decrease in
tumor growth within the KrasG12D/+;p53R172H/+ mouse model.
It was determined that within the KrasG12D/+;p53R172H/+ activated mouse model,
that LIN28B transcripts were elevated2.

LIN28B is a pluripotent factor that is

overexpressed in some cancers and mediates part of its pro-tumorigenic capabilities
through the post-transcriptional inhibition of let-7 biogenesis3–5. Since LIN28B inhibits
the tumor suppressive capabilities of let-7, it was hypothesized that let-7 targets would be
dysregulated within the activated KrasG12D/+;p53R172H/+ mouse model. One target of let-7
is that of MYC, a well known oncogene that is overexpressed in approximately 30% of
all cancers22,23.

The expression of MYC was assessed within lung tissues of the

KrasG12D/+;p53R172H/+ activated model compared to lungs harvested from nontumorigenic mice. The expression of canonical MYC was not affected by activation of
the transgenic model but a truncated MYC protein product was overexpressed in the
KrasG12D/+;p53R172H/+ activated model compared to non-tumorigenic lung tissue, seen in
Figure 4.

This led to the hypothesis that increased LIN28B expression causes the

accumulation of pri-let-7a-1 transcripts, which promotes the expression of the truncated
MYC protein product, termed T-MYC.
To understand if T-MYC was indeed a truncated form of canonical MYC, several
strategies were employed. The induction of T-MYC was proven to be reproducible in
vitro, seen in Figure 5 by transfection of the lenti-pri-let-7a-1 plasmid also used in
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transduction of the activated KrasG12D/+;p53R172H/+ model. This finding confirmed that TMYC expression could be replicated both in vitro and in vivo. T-MYC was also only
detected with multiple primary antibodies generated to detect the C-terminus of MYC in
SDS-PAGE and immunoblotting, seen in Figure 6, but not with an antibody that binds to
an epitope on the N-terminus of MYC. This result led to the hypothesis that T-MYC is a
truncated form of canonical MYC that retains only the C-terminus of MYC but does not
contain the N-terminus of MYC within its protein structure. In an attempt to further
characterize T-MYC, small-interfering RNA (siRNA) mediated knock-down was
employed with the hypothesis that if T-MYC is a protein variant of MYC, it would be
knocked down when co-transfected with a siRNA targeting MYC in A549 cells. As seen
in Figure 7, canonical MYC was noc ed do n

it si

s targeting ot t e

and

end of the MYC transcript, determined through SDS-PAGE and immunoblotting.
However, T-MYC was only knocked down with the siRNA designed to target the

end

of MYC. This led to the hypothesis that a transcript variant separate from the canonical
MYC transcript was being expressed with the transfection of the plasmid that promoted
the expression of T-MYC, lenti-pri-let-7a-1. To understand if a T-MYC transcript variant
was induced upon expression of T-MYC, A549 cells were co-transfected with lenti-prilet-7a-1 and a control scrambled siRNA sequence or a siRNA targeting the

end of MYC.

As seen in Figure 8, the expression of canonical MYC was unchanged by the transfection
of lenti-pri-let-7a-1 and a control siRNA but decreased when lenti-pri-let-7a-1 was cotransfected with the siRNA targeting MYC, as expected. Through using qPCR, it was
found that the expression of MYC transcripts was unchanged when T-MYC was induced
and MYC expression decreased when the siRNA targeting MYC was co-transfected while
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T-MYC expression remained unchanged. Since the total expression of MYC did not
change when T-MYC was induced, it was concluded that T-MYC was not expressed
from a transcript variant of canonical MYC.

Additionally, since MYC expression

decreased both at the transcript and protein levels when cells were transfected with the
siRNA targeting MYC, it was concluded that T-MYC is also likely not a protein variant
of MYC.
The induced expression of T-MYC was first observed upon activation of the
KrasG12D/+;p53R172H/+ transgenic mouse model that has increased LIN28B transcript
levels2. T-MYC expression was also seen through transfection of the lentiviral plasmid
that overexpresses pri-let-7a-1, lenti-pri-let-7a-1, in cells that had detectable levels of
LIN28B expression, A549 and Calu6.

Since T-MYC expression was observed in

backgrounds with detectable LIN28B expression, it was hypothesized that the LIN28B
mediated accumulation of pri-let-7a-1 transcripts induced the expression of T-MYC. To
test this hypothesis, several plasmids based off of lenti-pri-let-7a-1 were created. The
pri-let-7a-1 sequence was removed from the lenti-pri-let-7a-1 plasmid, termed lenti-Δprilet-7a-1, and was also cloned into a non-lentiviral backbone, termed pPNB-1. These
constructs, along with a lentiviral plasmid that overexpressed pri-let-7b, were transfected
in H441 and A549 lung adenocarcinoma cell lines. As seen in Figure 9, only the
plasmids that were based on the original lentiviral construct, lenti-pri-let-7a-1 and lentiΔpri-let-7a-1, promoted the expression of T-MYC. This finding indicated that neither
pri-let-7a-1 nor other let-7 family members, pri-let-7b, induce the expression of T-MYC.
Additionally, since T-MYC expression was seen in both cells that have LIN28B
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expression, A549, and cells that do not express LIN28B, H441, it was concluded that TMYC expression is not dependent on pri-let-7a-1 or LIN28B expression.
Finally, since expression of T-MYC was first observed simply by activation of the
KrasG12D/+;p53R172H/+ transgenic mouse model by exposing mice to adenovirus-cre
recombinase, it was hypothesized that T-MYC expression is conserved when cells are
transduced with virus. To test this hypothesis, H441 lung adenocarcinoma cells were
transduced with both lentivirus and adenovirus-cre recombinase and their cell lysates
were assessed for the expression of T-MYC through SDS-PAGE and immunoblotting.
As seen in Figure 10, T-MYC expression was not induced by either transduction with
lentivirus or adenovirus.

This finding indicates that T-MYC expression is not a

conserved effect seen by the transduction of cells with lentivirus or adenovirus.
It was originally hypothesized that the accumulation of unprocessed, primary-let7a-1 (pri-let-7a-1) transcripts by LIN28B promoted the expression of a truncated form of
MYC. Through this work, it was determined that pri-let-7a-1 does not promote the
expression of T-MYC and that T-MYC is likely not a protein variant of canonical MYC.
While this work does not explain why the lentiviral delivery of pri-let-7a-1 increases the
pro-tumorigenc phenotype in vivo, the elucidation of this effect could reveal additional,
unknown functions of the microRNA let-7. These findings could create a paradigm shift
in the understanding of the functions microRNAs and lead to the creation of effective
targeted therapies for the treatment of lung cancer.
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CHAPTER 5: MATERIALS AND METHODS

Cell Culture and Transfection
A549 and H441 lung adenocarcinoma cell lines were grown in 1X Gibco® RPMI
1640 supplemented with fetal bovine serum (FBS) and penicillin/streptoMYCin in a cell
culture incubator maintained at 37°C with 5% CO2. Passaging and maintenance of cells
took place in a biological safety cabinet under sterile conditions. For transfection, A549
cells were counted by using a hemocytometer and seeded at a volume of 2 mL at 2 x 10 5
cells/mL in sterile six well plates on Day 0.
com ining

Transfection occurred on Day 1 by

μL of Lipofectamine® 2000 transfection reagent it 1 μg of plasmid and if

co-transfected, with 25 nM of siRNA in serum and antibiotic free 1X Gibco® RPMI
1640. Four hours post transfection, serum free media was aspirated and replaced with 1X
Gibco® RPMI 1640 supplemented with FBS and penicillin/streptoMYCin.
Viral Transduction in Cell Culture
H441 lung adenocarcinoma cells were counted by using a hemocytometer and
seeded at a volume of 2 mL at 4 x 105 cells/mL in sterile six well plates on Day 0.
Tranduction occurred on Day 1 at a multiplicity of infection (MOI) of 2, therefore a total
concentration of 2 x 106 pfu

ere transduced.

2 μL of 1 x 109 pfu/mL feline

immunodeficiency virus (lentivirus) and 2 μL of 4 μg/μL poly rene stoc

ere com ined
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it 496 μL of serum and anti iotic free 1X Gi co®

PMI 1640, incu ated at room

temperature for 5 minutes and added to cells that had 1.5 mL serum and antibiotic free
1X Gibco® RPMI 1640 media.
serum/anti iotic free 1X Gi co®

00 μL of 4 x 106 pfu/mL adenovirus-cre diluted in
PMI 1640

as com ined

it 2.4 μL 2M CaCl 2,

incubated for 20 minutes at room temperature, and added to cells that had 1.5 mL serum
and antibiotic free 1X Gibco® RPMI 1640 media. One day post transduction, Day 2, the
media was aspirated and changed to 1X Gibco® RPMI 1640 media supplemented with
FBS and penicillin/streptoMYCin.
SDS-PAGE and Immunoblotting
48 hours post transfection or Day 3 (protocol seen above), cells were lysed with
1X radioimmunoprecipitation assay (RIPA) buffer supplemented with 1X protease
inhibitor cocktail with shaking for 10 minutes on ice. Remaining cellular debris was
scraped from plates and cell lysates were centrifuged at 13,200 rpm for 10 minutes. The
supernatant was moved to a new microcentrifuge tube and lysates were kept at -20°C
until needed. A Pierce BCA Protein Assay was then used to determine the concentration
of protein in each lysate fraction using a bovine serum albumin (BSA) standard curve. 50
μg of protein,

it 1X Laemli uffer supplemented

it 2-mercaptoethanol, was then

boiled at 95°C for 5 minutes. The protein containing samples were then loaded onto
Criterion™ TGX™ 12%, 12+2 com stac ing SDS polyacrylamide gels and run in an
electrophoretic chamber with 1X Tris-SDS-Glycine running buffer at 150 volts for 1 hour.
Protein was then transferred to polyvinylidene fluoride (PVDF) membranes activated for
5 minutes in methanol. The transfer occurred in a transfer chamber with 1X GlycineSDS-Methanol transfer buffer at 4°C under 100 volts for 50 minutes.
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The PVDF membranes were then blocked in Odyssey® Blocking Buffer (PBS)
with gentle shaking for 1 hour at room temperature. Primary MYC antibodies, at a
concentration of 1:500, were incubated on the PVDF membrane overnight at 4°C with
gentle shaking. Membranes were washed three times with phosphate buffer solution
supplemented with 0.01% Tween-20 (PBST) for 5 minutes with vigorous shaking.
Secondary antibodies, LI-COR IRDye® 680RD/800RD Goat anti-Mouse or Goat antiRabbit, were diluted in Odyssey® Blocking Buffer (PBS) at a concentration of 1:15,000
and incubated on the PVDF membranes for 1 hour at room temperature. Membranes
were then washed two times with phosphate buffer solution supplemented with 0.01%
Tween-20 (PBST) for 5 minutes with vigorous shaking followed by one wash with
phosphate buffer solution (PBS) for 10 minutes with vigorous shaking. Membranes were
then imaged on a LI-COR Odyssey® CLx infrared imager.

Primary β-Actin and

GAPDH antibodies were incubated on PVDF membranes at a concentration of 1:10,000
for one hour at room temperature, followed by the same protocol above for secondary
antibodies and imaging.
RNA Extraction and real-time PCR
RNA was extracted and purified from cell lysates post-transfection by direct lysis
of cells in six

ell plates

it 700 μL of QI zol Lysis eagent. Lysis and extraction of

RNA was then performed using the Qiagen® miRNeasy Mini Kit following the
manufacturer’s protocol of “Purification of Total

from

nimal Cells”.

T e

protocol was modified with a DNase digestion, protocol in Appendix B of the miRNeasy
Mini Handbook, using a Qiagen® RNase-Free DNase Set.
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Purified RNA was then quantified using a Thermo Scientific
UV-Vis Spectrop otometer. 1 μg of total

anoDrop™ 2000

as t en reverse transcri ed using a

miScript® HiFlex buffer in the Qiagen® miScript® II RT kit for 1 hour at 37°C followed
y minutes at 9 °C. T e 20 μL reverse transcription reaction was then diluted to a total
volume of 200 μL with nuclease free water and used in real-time polymerase chain
reaction (qPCR). qPCR was performed using the Qiagen® miScript® SYBR® Green
PC Kit, using 10 μL reaction sizes in 84

ell plates. Primer sets used are as follows:

MYC Exon 1/2 primer pair was generated using the NCBI Primer-BLAST program and
the

sequences

are

as

GGGAGGCTATTCTGCCCATT-

follows:

MYC

Exon

1/2

Forward:

-

and

MYC

Exon

1/2

Reverse:

-

GAGGCTGCTGGTTTTCCACT- . The MYC Exon 2/3 and Actin primer pairs were
commercially generated Qiagen® Quantitect Primer Assays. qPCR was performed on an
pplied Biosystems QuantStudio™ 6 Flex

eal-Time PCR system using the following

thermal cycling conditions; Initial Hold Stage: 95°C for 15 minutes, PCR Stage: 40
cycles of denature at 95°C for 15 seconds, anneal at 55°C for 30 seconds, and extension
with fluorescence data capture at 70°C for 30 seconds, and Melt Curve Stage: 95°C for
15 seconds, 60°C for 1 minute, and 95°C for 15 seconds with fluorescence data capture.
Ct values obtained from qPCR were analyzed using the comparative Ct method using
Actin as a gene for normalization of gene expression and the control transfection as the
internal control for gene expression comparison.
Cloning
Lenti-pri-let-7a-1 plasmids were propagated from pre-existing glycerol stocks in
the lab kept at -80°C. Cells were grown in 4 mL overnight cultures in liquid Luria Broth
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(LB) supplemented

it

100 μg/mL of ampicillin

it

vigorous s a ing at

7°C.

Plasmids were extracted from bacterial cells using a Qiagen® QIAprep® Spin Miniprep
Kit

and

quantified

using

a

T ermo

Scientific

anoDrop™

2000

UV-Vis

Spectrophotometer.
Lenti-Δpri-let-7a-1 was created by excising the pri-let-7a-1 sequence from the
lenti-pri-let-7a-1 plasmid.

This was done by performing a double restriction

endonuclease digestion of 1 μg of lenti-pri-let-7a-1 with the restriction endonucleases
eI and PacI from
used along

e

England Biola s® ( EB®).

20 μL reaction volume

as

it 0. μL of each NheI and PacI supplemented with 1X NEB® CutSmart®

Buffer for 1 hour at 37°C and heat inactivated at 65°C for 20 minutes.
filled in and

overhangs were removed by using NEB® T4 DNA Polymerase. The

reaction was carried out by adding 1 unit of T4 D
supplemented

overhangs were

polymerase per μg of D

,

it 100 μM d TPs and incu ated on a t ermal cycler for 1 minutes at

12°C. The reaction was then run on a 1% agarose gel with a Promega 1kb DNA ladder at
100 volts for 1 hour. The gel was visualized on a UVP Benchtop 2 Transilluminator and
the digested band was extracted from the gel. The DNA was then extracted from the
agarose gel using a Qiagen® QI quic ® gel extraction it. 100 ng of plasmid in a 10 μL
volume

as t en ligated

it 1 μL of

EB® T D

ligase and 10 μL of 2X T D

ligase buffer and occurred at room temperature overnight. Ligated plasmids were then
transformed in NEB® 5-alpha Escherichia coli competent cells. NEB® 5-alpha cells
were thawed on ice for 30 minutes, 100 ng of ligated plasmid

as added to 0 μL of

competent cells and incubated on ice for 30 minutes. The cells were heat-shocked by
placing the tube in a 42°C water bath for 45 seconds followed immediately by incubation
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on ice for 2 minutes. 2 0 μL of SOC media

as added to the cells in a microcentrifuge

tube and was then incubated at 37°C for 45 minutes with vigorous shaking. The total
volume as t en spread onto LB agar plates supplemented
and grown overnight at 37°C.

it 100 μg/mL of ampicillin

Multiple colonies were picked and grown in 4 mL

overnig t cultures in liquid LB supplemented

it

100 μg/mL of ampicillin

it

vigorous shaking at 37°C. Plasmids were finally extracted from bacterial cells using a
Qiagen® QIAprep® Spin Miniprep Kit followed by confirmation restriction
endonuclease digestion and sequencing of the plasmid at the Purdue low throughput
sequencing lab.
pPNB-1 was created by polymerase chain reaction (PCR) amplification of pri-let7a-1 from lenti-pri-let-7a-1 and cloning into pTet-4a, a non-lentiviral plasmid maintained
in the lab. pri-let-7a-1 was PCR amplified from lenti-pri-let-7a-1 using the following
primer

pairs

generated

using

NCBI

Primer-BLAST:

GTACGTACGGCCGCCTCCCCGCCTTAATTA-

and

let-7a-1_clon_F:
let-7a-1_clon_R:

-

GAGATTTAAATACCTTGCTAGCGGCGCGCCAT- . PCR was carried out by using
NEB® Q5® High Fidelity DNA Polymerase using the following conditions for each
reaction:

μL X Q

eaction Buffer, 0. μL of 100 μM d TPs, 1.2 μL of 10 μM

forward and reverse primer, 10 ng of lenti-pri-let-7a-1 plasmid D

, 0.2 μL Q ® D

Polymerase and 1 .7 μL nuclease free ater. T e PC t ermal cycling conditions used
are as follows: initial denaturation at 98°C for 30 seconds, 30 cycles of: denature at 98°C
for 10 seconds, anneal at 60°C for 30 seconds and extension at 72°C for 1.5 minutes,
followed by a final extension at 72°C for 5 minutes and hold at 4°C. Reactions were then
run on a 1% agarose gel with the Promega 1kb DNA ladder at 100 volts for 1 hour.
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Bands were extracted from the gel and DNA was extracted from the agarose gel using a
Qiagen® QIAquick® gel extraction kit. The PCR amplified product and pTet-4a were
t en digested to create compati le ends for ligation. 1 μg of eac

ere first digested it

SwaI supplemented with with NEB® Buffer 3.1. The reaction components for digestion
of t e PC product are as follo s: 1 μL S aI, 0 μL PC
and 14 μL of deionized
as follo s: 4. μL D

product,

μL

EBuffer .1

ater. T e reaction components for digestion of t e pTet-4a are
, 2 μL

EBuffer .1, 0. μL S aI and 1 .2 μL of deionized

water. Both reactions were incubated at 25°C for 1 hour followed by inactivation at 65°C
for 20 minutes. 1 μL of BsiWi as t en added to eac reaction and incu ated at

°C for

one hour. Digested pTet-4a was run on a 1% agarose gel with the Promega 1kb ladder
and its DNA was extracted from the agarose gel using the Qiagen® QIAquick® gel
extraction kit. The digested PCR insert was purified using the Qiagen® QIAquick®
Purification kit. The digested pTet-4a vector was ligated to the digested pri-let-7a-1
insert at a molar ratio of 1:3 by using NEB® T3 DNA ligase.

The reaction was

performed as follo s: 1 μL digested pTet-4a, 6 μL digested pri-let-7a-1 DNA insert, 10
μL EB® T D

ligase uffer and 1 μL EB® T D

ligase. The reaction was left

at room temperature overnight. Ligated plasmids were then transformed in NEB® 5alpha Escherichia coli competent cells. NEB® 5-alpha cells were thawed on ice for 30
minutes, 100 ng of ligated plasmid

as added to 0 μL of competent cells and incubated

on ice for 30 minutes. The cells were heat-shocked by placing the tube in a 42°C water
at for 4 seconds follo ed immediately y incu ation on ice for 2 minutes. 2 0 μL of
SOC media was added to the cells in a microcentrifuge tube and was then incubated at
37°C for 45 minutes with vigorous shaking. The total volume was then spread onto LB
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agar plates supplemented

it 100 μg/mL of ampicillin and gro n overnig t at 7°C.

Multiple colonies were picked and grown in 4 mL overnight cultures in liquid LB
supplemented

it 100 μg/mL of ampicillin

it vigorous s a ing at 7°C. Plasmids

were finally extracted from bacterial cells using a Qiagen® QIAprep® Spin Miniprep Kit
followed by confirmation restriction endonuclease digestion and sequencing of the
plasmid at the Purdue low throughput sequencing lab.
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